touchLearning Activities
Education, Conference Coverage and Articles
Late-breaking phase 3 data presented at ASCO 2026 highlight mezigdomide, an oral CELMoD, as a potential new option for patients with relapsed/refractory multiple myeloma previously exposed to anti-CD38 monoclonal antibodies and lenalidomide.
Several important lymphoma studies presented at ASCO 2026 provided new data across newly diagnosed and relapsed/refractory disease settings. The studies spanned aggressive B-cell lymphomas and classic Hodgkin lymphoma, evaluating novel antibody-based combinations, epigenetic targeting strategies and chemotherapy-sparing approaches. Dr Tycel Phillips provides his expert insights into the six most important studies of the meeting.
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical ...
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
In proud collaboration with EBMT, we have captured the highlights from the recent 52nd Annual Meeting, EBMT 2026. Below, hear from Dr Anna Sureda, President of EBMT, Dr Rafael Duarte, Congress President, and other world-leading experts sharing some of the most ...
At EBMT26, Prof Claire Booth presented a plenary session on gene therapy in primary immunodeficiencies. In this interview, she reflects on the field’s most important milestones, how gene therapy compares with allogeneic transplantation, and the critical challenge of ensuring patients can actually access these transformative treatments.
HSV infection remains a persistent and often debilitating complication in immunocompromised patients, particularly following transplantation. At EBMT26, Dr Genovefa Papanicolaou presented results from the phase III PRIOH-1 trial, highlighting the efficacy and safety of pritelivir – an oral antiviral with the potential to reshape management of acyclovir-resistant HSV.
At EBMT26, Prof Meral Beksac discusses data from the phase III PERSEUS trial, where adding daratumumab to standard VRd induction and consolidation – followed by daratumumab–lenalidomide maintenance – has delivered striking gains in sustained MRD negativity and progression-free survival. The findings reinforce a shift toward quadruplet therapy as the new standard of care in TE NDMM.
At EBMT26, Dr Roni Shouval presented his plenary abstract: a novel approach to one of the field’s persistent challenges: scalable, real-time immune monitoring following CAR-T therapy. In this interview, Dr Shouval discusses the clinical rationale, technological framework, and future implications of this emerging methodology.
At EBMT26, Prof Florent Malard presented the final results of the phase III ARES trial evaluating fecal microbiota transfer MAAT013 in a challenging clinical setting: ruxolitinib-refractory acute graft-versus-host disease (GvHD) with gastrointestinal involvement. With few effective options and poor outcomes in this setting, the study highlights how this novel microbiome-based, immunomodulatory approach by restoring gut microbiome diversity to modulate the immune system could redefine third-line treatment.
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Following the successful introduction of touchHAEMATOLOGY Future Leaders 2025, we are delighted to announce that nominations are now open for the 2026 shortlist.
In this edition of Haematology Horizons, we speak with Dr Hannah Levavi about the transformative role of immunotherapy in ALL. Dr. Levavi highlights how agents such as blinatumomab, inotuzumab and CD19-directed CAR-T therapies are reshaping frontline approaches, particularly for older or unfit patients traditionally unable to tolerate intensive chemotherapy.
In this Haematology Horizons practice pearl, Dr Hannah Levavi explores how CAR-T therapy is transforming adult ALL care—especially for older or unfit patients previously ineligible for transplant. She highlights early-use strategies, reduced-intensity induction regimens and promising developments like allogeneic CAR-T and novel antigen targets.
Key takeaways Primary endpoint not met, but promising trends observed – The Galleri® test did not achieve a statistically significant reduction in combined Stage III–IV cancer diagnoses, but showed favourable shifts toward earlier detection in 12 high-risk cancers. Reduction in late-stage ...
The 19th European Association for Haemophilia and Allied Disorders (EAHAD) Annual Congress, held in Dublin from 3-6 February 2026, showcased many exciting novel advancements in haemophilia care. Below, learn more about the highly anticipated late-breaking abstracts, showcasing fresh, innovative thinking that ...
As part of our Haematology Horizons practice pearl series, Dr Douglas Tremblay (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) explores the contemporary role and limitations of HMAs across chronic myelomonocytic leukaemia subtypes, contrasts treatment goals by patient fitness and transplant eligibility and looks ahead to emerging HMA combinations and novel agents designed specifically for CMML.
As part of our Haematology Horizons practice pearl series, Dr Douglas Tremblay (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) shares his expert insights on how luspatercept and imetelstat are reshaping first- and second-line treatment strategies for lower-risk MDS. He shares practical insights on patient selection, sequencing therapy, managing cytopenias and where the greatest unmet needs remain in contemporary practice.
touchHEMATOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
